oncolytic virus link, page-6

From that article: "In the US, the development of PD-1 medications was hailed as a breakthrough and fast-tracked by the Food and Drug Administration"....and "“It won’t be 100 per cent successful..."

And from VLA's own publications: "Promising results in a preclinical study when CAVATAK™ used in
conjunction with anti-PD-1 antibodies supports combination clinical trial".

Wouldn't it be nice if the combo therapy could be fast-tracked!